Search results for "infected patient"

showing 10 items of 19 documents

Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Fou…

2018

Objectives: The management of HIV disease is complicated by the incidence of a new spectrum of comorbid noncommunicable diseases (NCDs). It is important to document changes in the prevalence of NCDs over time. The aim of the study was to describe the impact of ageing on HIV markers and on the prevalence of NCDs in people living with HIV (PLWHIV) in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) seen for care in 2004–2014. Methods: Analyses were conducted separately for a closed cohort (same people seen at both times) and an open cohort (all people under follow-up). We used the χ2 test for categorical factors and the Wilcoxon test for quantitative factors to compare pro…

0301 basic medicineAdultMalemedicine.medical_specialtynoncommunicable diseases (NCDs); persons living with HIV (PLWHIV); time trend; Health Policy; Infectious Diseases; Pharmacology (medical)persons living with HIV (PLWHIV)PopulationRenal functionInfectious DiseaseHIV InfectionsDiseaseComorbiditySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinePrevalenceMedicineHiv infected patientsHumansPharmacology (medical)030212 general & internal medicineeducationDyslipidemiaseducation.field_of_studynoncommunicable diseases (NCDs); persons living with HIV (PLWHIV); time trendFramingham Risk Scorebusiness.industryIncidence (epidemiology)Health Policynoncommunicable diseases (NCDs) persons living with HIV (PLWHIV) time trendMiddle Aged030112 virologytime trendInfectious DiseasesItalyCardiovascular DiseasesCohortHypertensionFemalebusinessnoncommunicable diseases (NCDs)HIV medicine
researchProduct

Oral manifestations, salivary flow rates and Candida species in Thai HIV-infected patients

2019

Background Effects of various Highly Active Antiretroviral Therapy (HAART) regimens on oral heath are unclear. Objectives: We aimed to evaluate effects of HAART on oral manifestations, salivary flow rates (SFR) and Candida species in HIV-infected patients who took mostly non-protease inhibitor-based HAART regimens. Material and methods A cross-sectional study was performed on HIV-infected patients taking and never taken HAART who attended Thai Red Cross AIDS Research Centre (n = 48). Non-HIV subjects were recruited as control (n = 20). Oral conditions and salivary flow rates were evaluated using oral examination and measurement of unstimulated and stimulated saliva. In addition, Candida col…

0301 basic medicineSalivamedicine.medical_specialty030106 microbiology03 medical and health sciences0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)immune system diseasesInternal medicineHiv infected patientsMedicine030212 general & internal medicineGeneral DentistryColony-forming unitOral Medicine and Pathologybusiness.industryResearchvirus diseases:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseAntiretroviral therapyHyperpigmentationCorpus albicansSensitivity testUNESCO::CIENCIAS MÉDICASmedicine.symptombusiness
researchProduct

Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study

2021

Background. High-resolution estimates of HIV burden across space and time provide an important tool for tracking and monitoring the progress of prevention and control efforts and assist with improving the precision and efficiency of targeting efforts. We aimed to assess HIV incidence and HIV mortality for all second-level administrative units across sub-Saharan Africa. Methods. In this modelling study, we developed a framework that used the geographically specific HIV prevalence data collected in seroprevalence surveys and antenatal care clinics to train a model that estimates HIV incidence and mortality among individuals aged 15–49 years. We used a model-based geostatistical framework to e…

0301 basic medicinesub-Saharan AfricaMaleHIV AntibodieEpidemiologyHIV incidencesHIV Infectionsmortality rateHIV AntibodiesModelling studyHuman immunodeficiency virus prevalence0302 clinical medicineAfrica NorthernRA0421Seroepidemiologic StudiesMedicineNorthernHIV Infection030212 general & internal medicineYoung adult10. No inequalityuncertaintyMozambique11 Medical and Health SciencesHIV mortalityMortality rateIncidence (epidemiology)Incidence1. No povertyHiv incidencearticleMauritaniaHuman immunodeficiency virus infected patientArticlestrackingMiddle Agedhealth care planning3. Good healthPeer reviewLesothoAIDSInfectious DiseasesQR180A990 Medicine and Dentistry not elsewhere classifiedFemaleprenatal careanti human immunodeficiency virus agentseroepidemiologyHumanAdultAdolescentAnti-HIV AgentsImmunologyantiretroviral therapyUnit (housing)03 medical and health sciencesYoung AdultbloodHuman immunodeficiency virus infectionVirologySeroprevalenceHumanshumanDeveloping CountriesEstimationAcquired Immunodeficiency SyndromeSubnational mappingsbusiness.industrySeroepidemiologic StudieHIVAnti-HIV AgentPREVENTION030112 virologymortalitymonitoring3121 General medicine internal medicine and other clinical medicineHuman immunodeficiency virus antibodyAfricabusinessHIV incidence ; HIV mortality ; Subnational mapping ; Sub-Saharan Africa ; Local burden of disease ; Public healthDemography
researchProduct

Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patien…

2012

Objective To investigate the relationship between response to antiretroviral therapy (ART), alcohol use and occurrence of a major coronary or other arterial disease event (CADE) in HIV-infected individuals. Design A cohort study. A Cox model was used to identify the correlates of a first occurrence of a major CADE. Setting The French ANRS CO8 APROCO-COPILOTE cohort was set up in 1997 to study clinical progression and patient-reported outcomes (PRO) after initiating a protease inhibitor-containing ART. Clinical data were retrieved from medical records. Self-administered questionnaires collected data on PRO and behaviours, including alcohol use. Participants Metabolic data were only available…

1683Pathologymedicine.medical_specialtyArterial disease03 medical and health sciences0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)Internal medicinemedicineHiv infected patients1506030212 general & internal medicine17060303 health sciences030306 microbiologyProportional hazards modelbusiness.industryResearchGeneral Medicinemedicine.diseaseAntiretroviral therapy3. Good healthInfectious DiseasesCohort1714businessAlcohol consumptionCohort studyBMJ Open
researchProduct

Within subject variability of HDL-cholesterol in HIV-infected patients

2019

Background and objective: Within-subject variability of cardiovascular risk factors may influence the development of cardiovascular disease. We aimed to improve knowledge on HDL-cholesterol variability and its clinical significance in HIV-infected patients, a population at high risk of cardiovascular disease.Methods: This was a cohort study to quantify the variability of HDL-cholesterol between two consecutive visits and to determine factors associated with such variability, in a group of HIV-infected patients.Results: A total of 307 patients were included, mean ± standard deviation of their age was 45.1 ± 8.5 years, and 225 of them (73.3%) were male. The absolute difference (after squaring…

AdultBlood GlucoseMalemedicine.medical_specialtyAlcohol DrinkingWithin personPopulationBlood PressureHIV Infections030209 endocrinology & metabolismAbsolute difference030204 cardiovascular system & hematologyStandard deviationCigarette SmokingCohort Studies03 medical and health scienceschemistry.chemical_compoundSex Factors0302 clinical medicineHeart RateRisk FactorsInternal medicinemedicineHumansHiv infected patientsClinical significanceeducationeducation.field_of_studyCholesterolbusiness.industryCholesterol HDLAge FactorsGeneral MedicineMiddle AgedLipidsAnti-Retroviral AgentschemistryFemalelipids (amino acids peptides and proteins)businessCohort studyPostgraduate Medicine
researchProduct

Vitamin D supplementation, bone turnover, and inflammation in HIV-infected patients

2018

IF 1.307 (2017); International audience; ObjectiveTo assess whether vitamin D supplementation could be associated with a modification of inflammatory markers and bone turnover in HIV-1-infected patients.Patients and methodsPatients who participated in an initial survey in 2010 and who were followed in the same department were included in a new study in 2012. Between 2010 and 2012, vitamin D supplementation was offered to patients presenting with hypovitaminosis D as per appropriate guidelines. Clinical examinations were performed, and fasting blood samples were taken for inflammation and bone marker evaluations.ResultsOf the 263 patients who participated in the 2010 study, 198 were included…

AdultMale0301 basic medicinemedicine.medical_specialtyHypovitaminose DHIV InfectionsInflammationGastroenterologyBone remodeling03 medical and health sciences0302 clinical medicineHypovitaminosisN-terminal telopeptideTraitement antirétroviral[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInternal medicinemedicineVitamin D and neurologyHumansHiv infected patientsLongitudinal StudiesProspective Studies030212 general & internal medicineVitamin DInflammationVitamin d supplementationbusiness.industryHIVHypovitaminosis DVIHMiddle AgedVitamin D Deficiency16. Peace & justice030112 virologyAntiretroviral therapy3. Good healthInfectious DiseasesDietary SupplementsVitamine DFemaleBone Remodelingmedicine.symptombusinessBone markerMédecine et Maladies Infectieuses
researchProduct

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive …

2012

Background: The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission. While compensatory mutations increase fitness during treatment, their presence may also modulate viral fitness and virulence in absence of therapy and major resistance mutations. We previously designed a modeling technique that quantifies genotypic footprints of in vivo treatment selective pressure, including both drug …

AdultMalelcsh:Immunologic diseases. AllergyAnti-HIV AgentseducationVirulenceHIV InfectionsDrug resistanceBiologySettore MED/42 - Igiene Generale E ApplicataViruspolymorphism03 medical and health sciencesViral ProteinsSDG 3 - Good Health and Well-beingVirologyGenotypeDrug Resistance Viraldrug-naivemedicineHumansProspective Studies030304 developmental biology0303 health sciencesPolymorphism Genetic030306 microbiologyResearchproteaseViral LoadVirologyReverse transcriptase3. Good healthCD4 Lymphocyte CountDrug-naïveInfectious Diseases3121 General medicine internal medicine and other clinical medicineImmunologybiology.proteinHIV-1FemaleAntibodylcsh:RC581-607Viral loadHIV-1 infected patientmedicine.drugPeptide HydrolasesRetrovirology
researchProduct

A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.

2011

SUMMARYOptimal antiretroviral strategies for HIV-infected patients still need to be established. To this end a decision tree including different antiretroviral strategies that could be adopted for HIV-infected patients was built. A 10-year follow-up was simulated by using transitional probabilities estimated from a large cohort using a time-homogeneous Markov model. The desired outcome was for patients to maintain a CD4 cell count of >500 cells/mm3without experiencing AIDS or death. For patients with a baseline HIV viral load ⩾5 log10copies/ml, boosted protease inhibitor-based immediate highly active antiretroviral therapy (HAART) allowed them to spend 12% more time with CD4 ⩾500/mm3than…

AdultMalemedicine.medical_specialty[ INFO ] Computer Science [cs]EpidemiologyAnti-HIV AgentsDecision treeHIV InfectionsDrug Administration ScheduleCohort Studies03 medical and health sciences0302 clinical medicineLife ExpectancyAcquired immunodeficiency syndrome (AIDS)Internal medicineAntiretroviral Therapy Highly ActiveHiv infected patientsMedicineHumansProtease inhibitor (pharmacology)In patient[INFO]Computer Science [cs]Computer Simulation030212 general & internal medicineCd4 cell countComputingMilieux_MISCELLANEOUS0303 health sciences030306 microbiologybusiness.industryDecision TreesMiddle AgedViral Loadmedicine.diseaseAntiretroviral therapyMarkov Chains3. Good healthCD4 Lymphocyte CountInfectious DiseasesTreatment OutcomeImmunologyDisease ProgressionFemalebusinessViral loadFollow-Up StudiesEpidemiology and infection
researchProduct

Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades.

2021

Background The prognosis of HIV infection dramatically improved after the introduction of triple antiretroviral therapy 25 years ago. Herein, we report the impact of further improvements in HIV management since then, looking at all hospitalizations in persons living with HIV (PLWH) in Spain. Methods Retrospective study using the Spanish National Registry of Hospital Discharges. Information was retrieved since 1997 to 2018. Results From 79,647,783 nationwide hospital admissions recorded during the study period, 532,668 (0.67%) included HIV as diagnosis. The mean age of PLWH hospitalized increased from 33 to 51 years-old (p < 0.001). The rate of HIV hospitalizations significantly declined aft…

AdultPediatricsmedicine.medical_specialtyImmunologyHuman immunodeficiency virus (HIV)Hiv managementHIV Infectionsmedicine.disease_causeLiver diseaseAcquired immunodeficiency syndrome (AIDS)medicineImmunology and AllergyHiv infected patientsHumansRetrospective StudiesAcquired Immunodeficiency Syndromebusiness.industryRetrospective cohort studyKidney InsufficiencyMiddle Agedmedicine.diseaseHospitalizationInfectious DiseasesSpainNational registrybusinessAIDS (London, England)
researchProduct

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

2010

It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.

Liver CirrhosisANTIVIRAL TREATMENTHuman immunodeficiency virus (HIV)HIV InfectionsHepacivirusANTIVIRAL THERAPY; PEGYLATED INTERFERON-ALPHA-2B; LIVER-TRANSPLANTATION; PEGINTERFERON ALPHA-2A; HIV-INFECTED PATIENTS; VIRUS-COINFECTED PATIENTS; RAPID VIROLOGICAL RESPONSEAntiviral therapymedicine.disease_causeGastroenterologyPolyethylene GlycolsHBVguidelinesAcute hepatitisChronic hepatitisSettore MED/12 - Gastroenterologialiver transplantationGastroenterologyAntiviral therapyHepatitis CVIRUS-COINFECTED PATIENTSLIVER-TRANSPLANTATIONHepatitis CRecombinant Proteinsacute hepatitis; antiviral therapy; chronic hepatitis; cirrhosis; elderly patients; hbv; hcv; hdv; hiv; liver transplantationCLINICAL PRACTICE GUIDELINESCirrhosisHCVDrug Therapy CombinationAntiviral therapy Acute hepatitis Chronic hepatitisCirrhosis Elderly patients HBV HCV HDV HIV Liver transplantationElderly patientAcute hepatitiAcute hepatitismedicine.medical_specialtyGenotypePEGINTERFERON ALPHA-2AAlpha interferonHIV-INFECTED PATIENTSInterferon alpha-2CHRONIC HEPATITIS CAntiviral AgentsHepatitis B ChronicChronic hepatitisInternal medicineHDVDrug Resistance ViralRibavirinmedicineHumansPEGYLATED INTERFERON-ALPHA-2BCirrhosiHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAInterferon-alphaHIVHepatitis C Chronicmedicine.diseaseElderly patientsFamily medicineExpert opinionAntiviral therapy; Acute hepatitis; Chronic hepatitis; Cirrhosis; Elderly patients; HBV; HCV; HDV; HIV; liver transplantationChronic hepatitiRAPID VIROLOGICAL RESPONSEbusinessCHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; CLINICAL PRACTICE GUIDELINES
researchProduct